Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Trial details
- Registry ID
- NCT03257033
- Drugs studied
- Gemcitabine, RenovoCath, nab-paclitaxel
TrialRedline tracks 1 clinical trial sponsored by RenovoRx: 1 Phase 3.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPCNCT03257033 | Gemcitabine, RenovoCath, nab-paclitaxel | Active not recruiting | 2027-06Estimated |
Names as written in the registry records.
Before: Recruiting. After: Active not recruiting.
Before: Jun 2026. After: Jun 2027.